Indivior (NASDAQ:INDV) Releases Quarterly Earnings Results, Beats Estimates By $0.28 EPS

Indivior (NASDAQ:INDV) released its quarterly earnings results on Monday. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $0.28, Zacks reports. Indivior had a net margin of 26.65% and a negative return on equity of 310.69%. The company had revenue of $343.00 million during the quarter, compared to the consensus estimate of $306.23 million.

Here are the key takeaways from Indivior’s conference call:

• Positive Sentiment: The proposed all-stock merger would create a diversified CNS company with approximately $2.2 billion in pro forma revenue across addiction, ADHD, depression, and Parkinson’s disease, supported by 11 marketed medicines and five key growth products.
• Positive Sentiment: Management expects at least $125 million in annual cost synergies within the first 12 months after closing, primarily from G&A redundancies and operational efficiencies; pro forma adjusted EBITDA is estimated at $888 million, including the synergies.
• Positive Sentiment: SUBLOCADE, expected to represent roughly 44% of combined revenue, is described as the primary growth driver, with record new-patient starts, approximately 76% market share, and a long patent and manufacturing-complexity runway extending potentially into 2042–2044.
• Positive Sentiment: The combined balance sheet is expected to provide greater capacity for business development, with management targeting primarily mid- to late-stage CNS, psychiatry, neurology, and women’s-health assets while maintaining disciplined leverage of roughly 2.5x to 3.0x adjusted EBITDA.
• Negative Sentiment: The transaction remains subject to shareholder and regulatory approvals and customary closing conditions, with closing expected in the fourth quarter of 2026; management provided no formal forward earnings guidance beyond the pro forma figures.

Indivior Stock Down 0.1%

Shares of NASDAQ:INDV opened at $36.48 on Wednesday. Indivior has a twelve month low of $21.48 and a twelve month high of $42.81. The firm’s 50 day moving average price is $39.15 and its 200-day moving average price is $35.53. The stock has a market capitalization of $4.45 billion, a PE ratio of 18.71 and a beta of 0.86.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on INDV. Zacks Research lowered Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Barclays dropped their target price on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday. Craig Hallum reaffirmed a “buy” rating and issued a $53.00 target price on shares of Indivior in a research report on Tuesday. Finally, Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, July 24th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, Indivior presently has a consensus rating of “Moderate Buy” and an average price target of $45.17.

Insider Activity

In other Indivior news, insider Christian Heidbreder sold 18,586 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $41.14, for a total value of $764,628.04. Following the completion of the sale, the insider owned 209,337 shares in the company, valued at $8,612,124.18. This represents a 8.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ryan Preblick sold 36,000 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $37.70, for a total value of $1,357,200.00. Following the transaction, the chief financial officer owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. This trade represents a 11.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

A number of hedge funds have recently bought and sold shares of INDV. Raymond James Financial Inc. purchased a new stake in Indivior during the 2nd quarter valued at $26,000. Quarry LP bought a new position in Indivior during the 3rd quarter valued at about $26,000. Aquatic Capital Management LLC purchased a new stake in Indivior in the 3rd quarter worth about $104,000. California State Teachers Retirement System bought a new stake in Indivior in the second quarter worth about $112,000. Finally, Tower Research Capital LLC TRC lifted its stake in Indivior by 851.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,567 shares of the company’s stock worth $156,000 after purchasing an additional 9,456 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.